ASCO 2022 | Targeting HER2 in colorectal cancer

So, this is an exciting time for research in colorectal cancer as well. For HER2 positive colorectal cancer, we’ve already seen very favorable efficacy from the antibody drug conjugate, trastuzumab deruxtecan. Additionally, initial results of looking at tucatinib and trastuzumab in patients with HER2 positive colorectal cancer have been favorable. We look forward to presenting the full results of the MOUNTAINEER trial, which examines tucatinib and trastuzumab in HER2 positive colorectal cancer. Those results will be shown in early July at ESMO World GI. It is my hope that one day, we will have several FDA approved options for these patients with HER2 positive colorectal cancer. And ultimately, we are becoming much smarter about how we treat colorectal cancer in-general. Picking individual biomarkers with highly active therapies, and then matching that patient with the best available therapy to reduce toxicity, and also to help them live with a better quality of life. So, that’s an exciting development.